Role of systemic inflammatory response markers in urological malignancy

Area of Science:

• Oncology
• Clinical Pathology
• Biomarkers

Background:

• Systemic inflammation significantly impacts cancer patient survival across various malignancies.
• Peripheral blood markers, including serum proteins and cell counts, effectively monitor this inflammatory response.
• Established indices like the Glasgow Prognostic Score and prognostic nutritional index combine these markers for enhanced prognostic evaluation.

Purpose of the Study:

• To review the prognostic and predictive value of systemic inflammatory response markers in urological cancers.
• To highlight key markers such as C-reactive protein, Glasgow Prognostic Score, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index.
• To discuss the clinical utility and implications of these easily measurable, inexpensive markers.

Main Methods:

• Literature review of studies evaluating systemic inflammatory markers in urological cancer.
• Analysis of both pre-treatment and post-treatment marker values.
• Focus on commonly used indices: C-reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and prognostic nutritional index.

Main Results:

• Hundreds of studies confirm the prognostic significance of systemic inflammatory markers in urological cancers.
• Pre-treatment marker values are most frequently studied for prognostic and predictive roles.
• These markers are readily available and cost-effective in clinical settings.

Conclusions:

• Systemic inflammatory markers are vital, accessible tools for assessing prognosis in urological cancer patients.
• Understanding these markers aids clinicians in patient management and treatment planning.
• Further integration of these markers into clinical practice can improve patient outcomes.